Sugi Predict

Sugi Predict / Compounds / SCHEMBL16513553

SCHEMBL16513553

SCHEMBL16513553

c1ccc(-c2cccc3cnc(Nc4ccc(N5CCNCC5)cc4)nc23)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JUN P05412 3/20 0.66
▸ MAPK8 P45983 3/20 0.66
▸ MAPK10 P53779 3/20 0.66
▸ CDK4 P11802 6/20 0.56
▸ CCND1 P24385 5/20 0.56
▸ CDK2 P24941 5/20 0.56
▸ CCNE1 P24864 4/20 0.56
▸ CDK1 P06493 3/20 0.56
▸ CCNB1 P14635 3/20 0.56
▸ TTK P33981 2/20 0.55
▸ JAK2 O60674 3/20 0.55
▸ BRD4 O60885 3/20 0.55
▸ CCNA2 P20248 2/20 0.54
▸ PTK2 Q05397 2/20 0.54
▸ FGFR2 P21802 2/20 0.53
▸ EGFR P00533 1/20 0.52
▸ CDK6 Q00534 1/20 0.52
▸ JAK3 P52333 3/20 0.51
▸ JAK1 P23458 2/20 0.50
▸ BRD2 P25440 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16514398 0.89 JAK2 (0.56) JUNMAPK8MAPK10CDK4CCND1
SCHEMBL29847770 0.89 JAK2 (0.56) JUNMAPK8MAPK10CDK4CCND1
SCHEMBL29847708 0.89 JAK2 (0.56) JUNMAPK8MAPK10CDK4CCND1
SCHEMBL16514185 0.89 JAK2 (0.56) JUNMAPK8MAPK10CDK4CCND1
SCHEMBL29847922 0.89 JAK2 (0.56) JUNMAPK8MAPK10CDK4CCND1
SCHEMBL16514760 0.89 JAK2 (0.56) JUNMAPK8MAPK10CDK4CCND1
SCHEMBL16513631 0.88 MAPK10 (0.79) JUNMAPK8MAPK10CDK4CCND1
SCHEMBL29847439 0.88 MAPK10 (0.79) JUNMAPK8MAPK10CDK4CCND1
SCHEMBL16514148 0.87 WEE1 (0.55) JUNMAPK8MAPK10CDK4CCND1
SCHEMBL16513492 0.87 MAPK10 (0.54) JUNMAPK8MAPK10CDK4CCND1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105682661-B Certain chemical entities, compositions, and methods 润新生物公司 2020-03-27 — — CN claimed
US-9849139-B2 Substituted quinazolines for inhibiting kinase activity NEUPHARMA, INC. (US) 2017-12-26 — — US claimed
US-20170196881-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY NEUPHARMA, INC. 2017-07-13 — — US claimed
US-9550770-B2 Substituted quinazolines for inhibiting kinase activity NEUPHARMA, INC. (US) 2017-01-24 — — US claimed
EP-3035936-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NeuPharma, Inc. (US) 2016-06-29 — — EP claimed
US-20150175601-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. 2015-06-25 — — US claimed
WO-2015027222-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. (US) 2015-02-26 — — WO claimed
US-20260102406-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY NEUPHARMA INC (US) 2026-04-16 — — US disclosed
EP-3508204-B1 QUINAZOLIN-8-YL DERIVATIVES FOR USE IN METHODS OF TREATING MELANOMA, NON-SMALL CELL LUNG CANCER, THYROID CANCER, OVARIAN CANCER, OR COLON CANCER NEUPHARMA INC (US) 2026-02-11 — — EP disclosed
US-12403145-B2 Substituted quinazolines for inhibiting kinase activity NEUPHARMA, INC (US) 2025-09-02 — — US disclosed
US-20240197752-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY NEUPHARMA INC 2024-06-20 — — US disclosed
US-11865120-B2 Substituted quinazolines for inhibiting kinase activity NEUPHARMA, INC. (US) 2024-01-09 — — US disclosed
US-20220354864-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY NEUPHARMA, INC. 2022-11-10 — — US disclosed
US-9550770-B2 Substituted quinazolines for inhibiting kinase activity NEUPHARMA, INC. (US) 2017-01-24 — — US disclosed
EP-3035936-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NeuPharma, Inc. (US) 2016-06-29 — — EP disclosed
US-20150175601-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. 2015-06-25 — — US disclosed
US-20150175601-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. 2015-06-25 — — US disclosed
US-20150175601-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. 2015-06-25 — — US disclosed
WO-2015027222-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. (US) 2015-02-26 — — WO disclosed
WO-2015027222-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. (US) 2015-02-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170196881-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY DCK, ABL1, MAP4K2 JUN 1830/4885MAPK8 212/4885MAPK10 347/4885
US-20240197752-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY DCK, ABL1, MAP4K2 JUN 1830/4885MAPK8 212/4885MAPK10 347/4885
US-11865120-B2 Substituted quinazolines for inhibiting kinase activity DCK, ABL1, MAP4K2 JUN 1830/4885MAPK8 212/4885MAPK10 347/4885
US-20150175601-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS BRAF, PIK3CA, PLK1 JUN 3073/4885MAPK8 246/4885MAPK10 395/4885
US-12403145-B2 Substituted quinazolines for inhibiting kinase activity DCK, ABL1, MAP4K2 JUN 1830/4885MAPK8 212/4885MAPK10 347/4885
US-20220354864-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY DCK, ABL1, MAP4K2 JUN 1830/4885MAPK8 212/4885MAPK10 347/4885
US-20260102406-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY BRAF, TTK, MAP4K2 JUN 1577/4885MAPK8 65/4885MAPK10 220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.